VAIA
DCPH

Virtus Alternative Investment Advisers’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Virtus Alternative Investment Advisers’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-108
Closed -$6K – 246
2020
Q4 		$6K Sell
108
-105
-49% -$6.22K 0.09% 234
2020
Q3 		$11K Buy
+213
New +$10.4K 0.2% 232

Other funds holding DCPH

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Virtus Alternative Investment Advisers's DCPH Position: Q1 2021 in Review

Virtus Alternative Investment Advisers sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q1 2021, closing a stake of 108 shares — an estimated $6K sold.

Virtus Alternative Investment Advisers first reported a position in DCPH in Q3 2020 and held it in 2 quarters. The position peaked at $11K in Q3 2020. 167 funds tracked by Wall St. Rank hold DCPH as of Q1 2021.

  • Virtus Alternative Investment Advisers reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Virtus Alternative Investment Advisers sold 108 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q1 2021, an estimated $6K.
  • Virtus Alternative Investment Advisers first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • Virtus Alternative Investment Advisers's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $11K in Q3 2020.
  • 167 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q1 2021.

Based on Virtus Alternative Investment Advisers's 13F filing for Q1 2021.